Investigational drug · Phase 2
VDMN-21
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Verruca Vulgaris, Warts, Common Wart.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "VDMN-21"
First trial start
2023
Feb 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VDMN-21", any sponsor or status.
Conditions studied
As listed on its trial records.
- Verruca Vulgaris
- Warts
- Common Wart
Largest trials
Live from ClinicalTrials.gov: studies naming "VDMN-21" as an intervention, largest first.
- Safety and Efficacy of VDMN-21 Patch in Subjects With Common WartsPivotal-lookingCompleted
Veradermics, Inc.Industry
NCT05799157 · 153 participants · Start Feb 28, 2023 · Primary completion Feb 25, 2025
Drug: VDMN-21 Patch Low Dose; VDMN-21 Patch High Dose and 1 more · For: Verruca Vulgaris; Warts; Common Wart
Sites: Fort Smith, Arkansas; San Diego, California; Plainfield, Indiana · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.